{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:39:51Z","timestamp":1772159991372,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T00:00:00Z","timestamp":1478476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co. Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ono Pharma UK Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2017,1]]},"abstract":"Summary<\/jats:title>\n \n Background<\/jats:title>\n \n ONO<\/jats:styled-content>\n \u20102952 is a novel and selective inhibitor of translocator protein 18\n kD<\/jats:styled-content>\n a that reduces stress\u2010induced defecation and visceral hyperalgesia in rat models.\n <\/jats:p>\n <\/jats:sec>\n \n Aim<\/jats:title>\n \n To evaluate the efficacy and safety of\n ONO<\/jats:styled-content>\n \u20102952 in females with irritable bowel syndrome with diarrhoea in an exploratory proof\u2010of\u2010concept study.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A randomised, double\u2010blind, placebo\u2010controlled study was conducted at 49\n US<\/jats:styled-content>\n centres. Two hundred subjects with irritable bowel syndrome with diarrhoea (Rome\n III<\/jats:styled-content>\n criteria) were randomised to\n ONO<\/jats:styled-content>\n \u20102952 20 mg, or 60 mg, or placebo. Subjects recorded irritable bowel syndrome symptoms daily during a 2\u2010week baseline period, the 4\u2010week treatment period and for 4 weeks post\u2010treatment. The co\u2010primary endpoints were change from baseline to week 4 in abdominal pain, stool consistency and stool frequency.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Improvements in irritable bowel syndrome symptoms were seen with\n ONO<\/jats:styled-content>\n \u20102952 over placebo in per\u2010protocol analyses for all three co\u2010primary endpoints, but these did not reach statistical significance at the 5% level. The largest improvement was seen with\n ONO<\/jats:styled-content>\n \u20102952 60 mg.\n ONO<\/jats:styled-content>\n \u20102952 was well tolerated with a safety profile similar to that of placebo. Most adverse events were mild or moderate in severity and not treatment related.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n ONO<\/jats:styled-content>\n \u20102952 showed evidence of clinical efficacy in reducing irritable bowel syndrome\u2010related symptoms in female subjects with irritable bowel syndrome with diarrhoea, and further evaluation is, therefore, warranted to assess its potential as a treatment for irritable bowel syndrome with diarrhoea (\n NCT<\/jats:styled-content>\n 01844180).\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/apt.13839","type":"journal-article","created":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T21:04:29Z","timestamp":1478552669000},"page":"14-26","source":"Crossref","is-referenced-by-count":18,"title":["Randomised clinical trial: exploratory phase 2 study of\n ONO<\/scp>\n \u20102952 in diarrhoea\u2010predominant irritable bowel syndrome"],"prefix":"10.1111","volume":"45","author":[{"given":"W. E.","family":"Whitehead","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Duffy","sequence":"additional","affiliation":[{"name":"Ono Pharma UK Ltd London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sharpe","sequence":"additional","affiliation":[{"name":"Ono Pharma UK Ltd London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Nabata","sequence":"additional","affiliation":[{"name":"Ono Pharma UK Ltd London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bruce","sequence":"additional","affiliation":[{"name":"Ono Pharma UK Ltd London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.02.029"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i40.11353"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.061"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.187"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-015-0243-3"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v6.i4.120"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.04128.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1757-4749-2-3"},{"key":"e_1_2_8_10_1","first-page":"1","article-title":"New and emerging treatment options for irritable bowel syndrome","volume":"11","author":"Lacy BE","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000362405"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-015-0068-5"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2016.1118052"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2010.06.013"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.12.004"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2006.06.005"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3295"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01808"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-004-4283-9"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-53630-3.00008-7"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.09.005"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.07.011"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)63164-3"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.07.010"},{"key":"e_1_2_8_25_1","unstructured":"FrankleWG NarendranR MasonSN et al.A phase I PET study to evaluate brain translocator protein occupancy by ONO\u20102952 in healthy adult subjects using 11C\u2010PBR28. Society for Neuroscience Annual Meeting 2014; Abstract BB21."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709011203"},{"key":"e_1_2_8_27_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration 2012 FDA Silver Springs MD 1 14"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01941.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.142318000.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006059802600203"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070486"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505180"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01282.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00284-8"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.14.1733"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05208.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900025815"},{"key":"e_1_2_8_38_1","first-page":"71","article-title":"The epidemiology of irritable bowel syndrome","volume":"6","author":"Canavan C","year":"2014","journal-title":"Clin Epidemiol"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13839","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13839","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.13839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:54:53Z","timestamp":1695473693000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/apt.13839"],"URL":"https:\/\/doi.org\/10.1111\/apt.13839","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727063853.793525962","asserted-by":"object"}]},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,7]]}}}